Million Dollar Gotham Prize Announced
A group of leading scientists and hedge fund managers have announced the annual $1 million Gotham Prize for Cancer Research, which is being launched to accelerate progress in the prevention, diagnosis, and treatment of cancer by fostering collaboration among top researchers in the field.
NEW YORKA group of leading scientists and hedge fund managers have announced the annual $1 million Gotham Prize for Cancer Research, which is being launched to accelerate progress in the prevention, diagnosis, and treatment of cancer by fostering collaboration among top researchers in the field.
The prize is open to prequalified individuals who share their ideas and concepts by posting a short thesis and/or proposal and answering questions at www.gothamprize.org, the Gotham Prize website. Each year, the member who submits the best idea in the area of cancer research as judged by an expert panel will receive $1 million for personal use. The annual $250,000 Ira Sohn Conference Foundation Prize in Pediatric Oncology will be awarded for the best idea in pediatric oncology. The 2007 winners will be revealed in February 2008.
The Gotham Prize website will serve as an ongoing forum for cancer researchers to test and exchange ideas. The website will also provide a mechanism to connect researchers with other potential sources of funding. The Gotham Prize was founded by Gary Curhan, MD, ScD, of Harvard Medical School, and investment managers from Gotham Capital, a private investment firm founded by Joel Greenblatt, MBA.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
